Physician profile
Neeti Kothare
NPI 1558898197
$1,339.91
in general payments reported to CMS, 2019-2025
29 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 96% of Hospice and Palliative Medicine (Family Medicine) providers received nationally (typical 2025 total: $78.57).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $24.29 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,339.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $134.47 | 2025 | Iclusig, Ninlaro, Fruzaqla |
| Merck Sharp & Dohme LLC | $111.88 | 2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals Lp | $103.72 | 2025 | Calquence, Imfinzi |
| Regeneron Healthcare Solutions, INC. | $96.52 | 2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $72.91 | 2025 | |
| Glaxosmithkline, LLC. | $70.48 | 2025 | Zejula, Jemperli, Trelegy Ellipta |
| Janssen Biotech, INC. | $69.26 | 2025 | Rybrevant, Darzalex, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $51.37 | 2025 | |
| Geron Corporation | $45.55 | 2025 | Rytelo |
| Tersera Therapeutics LLC | $44.76 | 2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $44.74 | 2025 | |
| Sobi, INC | $40.89 | 2025 | |
| Puma Biotechnology, INC. | $37.27 | 2025 | |
| Legend Biotech USA INC. | $36.87 | 2025 | Carvykti |
| Sun Pharmaceutical Industries INC. | $32.26 | 2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $31.33 | 2025 | Vyloy |
| Rigel Pharmaceuticals, INC. | $29.90 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Daiichi Sankyo INC. | $28.32 | 2025 | Enhertu |
| Incyte Corporation | $27.91 | 2025 | Monjuvi, Zynyz |
| Aveo Pharmaceuticals, INC. | $25.50 | 2025 | |
| Genzyme Corporation | $24.58 | 2025 | |
| Genmab U.S., INC. | $24.36 | 2025 | Epkinly |
| Novo Nordisk INC | $24.29 | 2024 | |
| Servier Pharmaceuticals LLC | $22.86 | 2025 | |
| Alexion Pharmaceuticals, INC. | $22.71 | 2025 | Ultomiris |
| Shield Therapeutics INC | $22.27 | 2025 | |
| Cycle Pharmaceuticals INC | $21.67 | 2025 | Phyrago |
| Eisai INC. | $21.27 | 2025 | |
| Karyopharm Therapeutics INC. | $19.99 | 2025 | Xpovio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeti Kothare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.